Actuate Therapeutics, Common Stock Performance
| ACTU Stock | 6.56 0.05 0.76% |
The firm shows a Beta (market volatility) of 1.09, which signifies a somewhat significant risk relative to the market. Actuate Therapeutics, returns are very sensitive to returns on the market. As the market goes up or down, Actuate Therapeutics, is expected to follow. At this point, Actuate Therapeutics, has a negative expected return of -0.0018%. Please make sure to confirm Actuate Therapeutics,'s treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Actuate Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Actuate Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Actuate Therapeutics, is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 3 M | |
| Free Cash Flow | -21.8 M |
Actuate Therapeutics, Relative Risk vs. Return Landscape
If you would invest 689.00 in Actuate Therapeutics, Common on September 26, 2025 and sell it today you would lose (33.00) from holding Actuate Therapeutics, Common or give up 4.79% of portfolio value over 90 days. Actuate Therapeutics, Common is currently does not generate positive expected returns and assumes 3.9512% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Actuate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Actuate Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actuate Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Actuate Therapeutics, Common, and traders can use it to determine the average amount a Actuate Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -4.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACTU |
Based on monthly moving average Actuate Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Actuate Therapeutics, by adding Actuate Therapeutics, to a well-diversified portfolio.
Actuate Therapeutics, Fundamentals Growth
Actuate Stock prices reflect investors' perceptions of the future prospects and financial health of Actuate Therapeutics,, and Actuate Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Actuate Stock performance.
| Return On Asset | -3.49 | ||||
| Current Valuation | 160.19 M | ||||
| Shares Outstanding | 23.24 M | ||||
| Price To Book | 14.05 X | ||||
| EBITDA | (25.16 M) | ||||
| Total Debt | 404.99 K | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (21.84 M) | ||||
| Earnings Per Share | (3.11) X | ||||
| Total Asset | 9.32 M | ||||
| Retained Earnings | (132.38 M) | ||||
About Actuate Therapeutics, Performance
Assessing Actuate Therapeutics,'s fundamental ratios provides investors with valuable insights into Actuate Therapeutics,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Actuate Therapeutics, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Actuate Therapeutics, performance evaluation
Checking the ongoing alerts about Actuate Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Actuate Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Actuate Therapeutics, generated a negative expected return over the last 90 days | |
| Actuate Therapeutics, has high historical volatility and very poor performance | |
| Actuate Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (27.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Actuate Therapeutics, generates negative cash flow from operations | |
| Actuate Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders |
- Analyzing Actuate Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Actuate Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Actuate Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Actuate Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Actuate Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Actuate Therapeutics,'s stock. These opinions can provide insight into Actuate Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics,'s price analysis, check to measure Actuate Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics, is operating at the current time. Most of Actuate Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics,'s price. Additionally, you may evaluate how the addition of Actuate Therapeutics, to your portfolios can decrease your overall portfolio volatility.